Understanding non-Hodgkin's lymphoma
Non-Hodgkin's lymphoma is the name for a large group of cancers that develop from lymphocytes (white blood cells). Non-Hodgkin's lymphoma begins when a white blood cell becomes abnormal. The abnormal cell divides to make copies of itself. The new cells divide again and again, making more and more abnormal cells. These abnormal cells don't die when they should and they don't protect the body from infections or other diseases. The buildup of extra cells often forms a mass of tissue called a growth or tumor.
Non-Hodgkin's lymphoma can occur at any age and is often identified by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of non-Hodgkin's lymphoma. These types can be divided into aggressive (fast-growing) and indolent (slow-growing) and they can involve either B-cells or T-cells. Prognosis and treatment depend on the stage and type of disease. For patients diagnosed with follicular non-Hodgkin's lymphoma, you may wish to consult www.zevalin.com for more information on treatment choices.
Your doctor will evaluate your type of non-Hodgkin's lymphoma and other factors to determine if you are a candidate for ZEVALIN. Your doctor will consider the percentage of lymphoma cells in your bone marrow, your blood cell counts and possible allergies or other reactions you may have to any component of ZEVALIN treatment.
Indications and Usage
ZEVALIN® (ibritumomab tiuxetan) injection for intravenous use is a prescription medication that has three parts: two infusions of rituximab and one injection of Yttrium-90 (Y-90) ZEVALIN. Rituximab is used to reduce the number of B-cells in your blood and Y-90 ZEVALIN is given to treat your non-Hodgkin's lymphoma (NHL).
The ZEVALIN therapeutic regimen is used to treat patients with: